Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Perioperative imatinib mesylate may shrink the tumor and may reduce the
chance of relapse after surgery. This phase II trial is studying the effectiveness of
perioperative imatinib mesylate in treating patients with locally advanced gastrointestinal
stromal tumor.